✦ LIBER ✦

Vaccination against HPV-16 Oncoproteins in Vulvar Intraepithelial Neoplasia

✍ Scribed by Corson, Stephen L.

Book ID: 123518520
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 52 KB
Volume: 17
Category: Article
ISSN: 1553-4650
DOI: 10.1016/j.jmig.2009.12.001

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Vaccination against HPV-16 Oncoproteins

Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia

✍ Kenter, Gemma G.; Welters, Marij J.P.; Valentijn, A. Rob P.M.; Lowik, Margriet J 📂 Article 📅 2009 🏛 Massachusetts Medical Society 🌐 English ⚖ 581 KB

Integration of HPV-16 and HPV-18 DNA in

Integration of HPV-16 and HPV-18 DNA in vulvar intraepithelial neoplasia

✍ Peter Hillemanns; Xiuli Wang 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 144 KB

HPV 16/18 vaccine prevents cervical intr

HPV 16/18 vaccine prevents cervical intraepithelial neoplasia

📂 Article 📅 2007 🏛 Adis International Limited (now part of Wolters Kl ⚖ 121 KB

Human papillomavirus type 16 in vulvar c

Human papillomavirus type 16 in vulvar carcinoma, vulvar intraepithelial neoplasia, and associated cervical neoplasia

✍ Ulla Hørding; Søren Daugaard; Astrid K.N. Iversen; Jens Knudsen; Johannes E. Boc 📂 Article 📅 1991 🏛 Elsevier Science 🌐 English ⚖ 502 KB

Cervical intraepithelial neoplasia grade

Cervical intraepithelial neoplasia grade 2 or worse in Galicia, Spain: HPV 16 prevalence and vaccination impact

✍ Pérez-Castro, Sonia; Lorenzo-Mahía, Yolanda; Iñarrea Fernández, Amparo; Lamas-Go 📂 Article 📅 2014 🏛 Elsevier Science 🌐 Spanish ⚖ 747 KB

Human papillomavirus (HPV) type 16-speci

Human papillomavirus (HPV) type 16-specific CD8+ T cell responses in women with high grade vulvar intraepithelial neoplasia

✍ Richard W. Todd; Sally Roberts; Christopher H. Mann; David M. Luesley; Phillip H 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 479 KB 👁 1 views

## Abstract Human papillomavirus (HPV)‐associated vulvar intraepithelial neoplasia (VIN) has serious sequelae for the sufferer. Current treatments are associated with poor response and high relapse rates. The development of HPV‐specific T cell immunotherapies offers a new approach to treatment. Thi